Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2025-12-25 @ 1:33 AM
NCT ID:
NCT02739594
Eligibility Criteria:
Inclusion Criteria:
* Confirmed multiple myeloma, Stage II-III as per Salmon and Durie (1975)
* Indication for biphosphonate therapy
Exclusion Criteria:
* Previous therapy with ibandronate or zoledronate within the past 12 months
* Renal insufficiency with serum creatinine \>3.0 mg/dL or \>265 micromoles per liter (µmol/L) or CrCl \<30 mL/min
* Hypersensitivity to ibandronate, zoledronate, or other biphosphonates
* Presence of secondary malignomas, apart from basaliomas and cervical carcinoma in situ
* Severe accompanying illness with organ impairment
* Osteonecrosis of the jaw at the start of the study
* Life expectancy ≤12 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02739594
Study Brief:
Protocol Section:
NCT02739594